Pars-plana Vitrectomy vs Panretinal Photocoagulation for Severe NPDR

NCT04103671 | Unknown DMC

• 1 other identifier: 2019KYPJ108
• Study Type: interventional
• Target: 272
• Locations: 1 country
• Sites: 1

Brief Summary

It is estimated that there are about 600 million diabetes mellitus (DM) patients all over the world until 2040，and almost 50% of whom have some degree of diabetic retinopathy (DR) at any given time. About 5% to 10% diabetic retinopathy would develop vision-threatening complications, including proliferative diabetic retinopathy (PDR), capillary non-perfusion, or macular edema. Data from the DRS suggest that given long enough duration of diabetes, approximately 60% of patients with DR will develop PDR, and without intervention, 75% nonproliferative diabetic retinopathy (NPDR) will development PDR within 1 year follow up, 45% will develop high-risk PDR, nearly half of PDR will experience profound visual loss. panretinal photocoagulation (PRP) only reduced 50% risk of sever visual loss and about 25% of the sNPDR patients who finished PRP need Pars-plana vitrectomy (PPV) in a 5 year follow up. Vitreous have been proven to play an important role in the development of NPDR to PDR, which were the collection of vascular endothelial growth factor (VEGF) factors and the major component of proliferative lesion in the later stage of PDR. Micro-invasive Pars-plana vitrectomy has been shown as a safe and effective method in the treatment of PDR, through removing the pathological vitreous, proliferative membrane and also the VEGF factors. However, whether or not Micro-invasive Pars-plana vitrectomy will be more effective than PRP to control the progression of NDPR remained unknown.

Conditions

Non Proliferative Diabetic Retinopathy

Keywords

NPDR; Pars-plana vitrectomy; panretinal photocoagulation

Outcome Measures

Primary Outcomes (1)

• progression rate of severe non proliferative diabetic retinopathy

  the number of patients with severe non proliferative diabetic retinopathy progressed to proliferative diabetic retinopathy in each group from the baseline to 12 months

  12 months

Secondary Outcomes (7)

• the change of best corrected visual acuity

  12 months

• the rate of re-treatment

  12 months

• The occurrence of diabetic macular edema

  12 months

• The change of central retinal thickness

  12 months

• The change of visual field

  12 months

Study Arms (2)

Group A

EXPERIMENTAL

Prompt panretinal photocoagulation

Procedure: Prompt panretinal photocoagulation

Group B

EXPERIMENTAL

Micro-invasive Pars-plana vitrectomy

Procedure: 25G Pars-plana vitrectomy

Interventions

Prompt panretinal photocoagulation PROCEDURE

Study eyes that receive panretinal photocoagulation (prompt PRP eyes at baseline) should have 1200 to1600 burns with a spot size on the retina of approximately 500 microns given over 1 to 3 sittings and completed within 4 weeks of initiation

Group A

25G Pars-plana vitrectomy PROCEDURE

Study eyes that receive standard 25G Pars-plana vitrectomy that remove all the vitreous, without laser or Silicone oil tamponade, but filled with perfusion fluid. Surgery should be completed within 4 weeks after randomization.

Group B

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Aged ≥18 years, male or female
• Type 1 or type 2 diabetes
• Presence of severe NPDR according to the diagnosis of 4-2-1 rule,
• One or more of the following, in the absence of PDR:
• More than 20 intraretinal hemorrhages in each of four quadrants
• Definite venous beading in two or more quadrants
• Prominent intraretinal microvascular abnormality (IRMA) in one or more quadrants
• Best corrected Electronic-Early Treatment Diabetic Retinopathy Study (E-ETDRS) visual acuity letter score \> 24 (approximate Snellen equivalent 20/320) on the day of randomization.
• Media clarity, pupillary dilation, and study participant cooperation sufficient to administer PRP and obtain adequate fundus photographs and optical coherence tomography (OCT).
• Able and willing to provide informed consent

You may not qualify if:

• Significant renal disease, defined as a history of chronic renal failure requiring dialysis or kidney transplant
• In the opinion of the investigator, A condition that would preclude participation in the study (e.g., unstable medical status including blood pressure, cardiovascular disease, and glycemic control).
• Participation in an investigational trial within 30 days of randomization that involved treatment with any drug that has not received regulatory approval for the indication being studied.
• Blood pressure \> 180/110 (systolic above 180 or diastolic above 110).
• \*If blood pressure is brought below 180/110 by anti-hypertensive treatment, individual can become eligible.
• Myocardial infarction, other acute cardiac event requiring hospitalization, stroke, transient ischemic attack, or treatment for acute congestive heart failure within 4 months prior to randomization
• Systemic anti-VEGF or pro-VEGF treatment within 4 months prior to randomization
• \* These drugs should not be used during the study
• For women of child-bearing potential: pregnant or lactating or intending to become pregnant within the next 3 years.
• \* Women who are potential study participants should be questioned about the potential for pregnancy. Investigator judgment is used to determine when a pregnancy test is needed
• History of prior panretinal photocoagulation (prior PRP is defined as ≥100 burns outside of the posterior pole
• If macular edema is present, it is considered to be primarily due to a cause other than diabetic macular edema.
• An ocular condition is present (other than diabetic retinopathy) that, in the opinion of the investigator, might alter visual acuity during the course of the study (e.g., retinal vein or artery occlusion, uveitis or other ocular inflammatory disease, neovascular glaucoma, etc.).
• Substantial cataract that, in the opinion of the investigator, is likely to be decreasing visual acuity by 3 lines or more (i.e., cataract would be reducing acuity to 20/40 or worse if eye were otherwise normal).
• History of intravitreal anti-VEGF treatment at any time in the past 2 months

Sponsors & Collaborators

• Zhongshan Ophthalmic Center, Sun Yat-sen University: lead

Study Sites (1)

Zhongshan Ophthalmic Center

Guangzhou, Guangdong, 510060, China

RECRUITING

Related Publications (1)

• Zheng W, Chen S, Ding X, Lai K, Xiao S, Lin Y, Liu B, Jin L, Li J, Wu Y, Ma Y, Lu L, Liu Y, Li T. Microinvasive pars plana vitrectomy versus panretinal photocoagulation in the treatment of severe non-proliferative diabetic retinopathy (the VIP study): study protocol for a randomised controlled trial. BMJ Open. 2021 Feb 22;11(2):e043371. doi: 10.1136/bmjopen-2020-043371.

  PMID: 33619191 DERIVED

Central Study Contacts

tao li, Dr

CONTACT

66683995; litao2@mail.sysu.edu.cn

shida chen, Dr

CONTACT

66610721; chenshd3@mail.sysu.edu.cn

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 23, 2019
• First Posted: September 25, 2019
• Study Start: December 4, 2019
• Primary Completion: December 31, 2024
• Study Completion: December 31, 2025
• Last Updated: March 30, 2023

Record last verified: 2023-03

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)